Stabilitech has ongoing collaborations with a number of pharmaceutical companies:

  • GSK: Stabilitech has entered into an option and license agreement with GSK to evaluate the company’s thermal stability platform technology
  • Zoetis: Zoetis (formerly Pfizer Animal Health) and Stabilitech entered a three-year collaboration to explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals
  • Oncolytic biotech [confidential]: Stabilitech entered into an option and license agreement with a confidential oncolytic biotech company to stabilize their lead clinical asset

Stabilitech seeks further partnership opportunities with pharma and biotech companies on:

  • Stabilitech’s internal pipeline
  • Therm-SB: providing thermal stability to partners assets (vaccines, vectors, viruses)
  • OraPro: efficaciously delivering partners vectors to the GI tract to transduce DNA products for host cells

 

Please contact [contact details]